In conclusion, these findings suggest that pemetrexed can affect the expression of PD-L1 on cancer cells either directly, by activating signaling pathways controlling PD-L1 transcription, or indirectly, through the release of IFN-γ by immune cells in the tumor microenvironment. This evidence concerns the gene IFNG and neoplasm.